Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemDiv has signed a multi-project research and collaboration deal with Janssen Pharmaceutica NV (Janssen) and Tibotec Pharmaceuticals (Tibotec) to identify novel small molecules against targets to be jointly agreed upon.
Subscribe to our email newsletter
ChemDiv is believed to make use of its expertise in drug discovery.
Janssen or Tibotec will fund certain R&D costs of ChemDiv for every research project and ChemDiv will be eligible for certain success milestones.
Under this arrangement, most of the research will be conducted by ChemDiv through its Moscow subsidiary, ChemDiv Research Institute (CDRI).
ChemDiv Research Institute chairman Nikolay Savchuk said collaborative risk sharing under this strategic arrangement is aimed at building up R&D productivity and broadening emerging market access.
"We are delighted to work with Janssen under a flexible entrepreneurial model more common to biotech ventures," Savchuk added.